Novel use of antihistamine agents for the preventative or early treatment of inflammatory syndromes,in particular those triggered by togaviruses
Patents Granted (Contd.) FORM 25 (12) PATENT (19) AP (11) Patent No: AP 2910 (73) Applicant(s) (21) Application No : AP/P/2008/004613 PIERRE FABRE MEDICAMENT 45 Place Abel Gance, 92100 Boulogne-billancourt, France (22) Filing Date: 09.03.2007 (45) (24) Publication: Date of Grant & 01.05.2014 (30) Priority Data (33) Country (31) Number (32) Date (72) Inventors FR 0602087 09.03.2006 DEREGNAUCOURT Jean, France ANDRE Etienne, France πSNE-VERSAILLES Jacky, France et al (84) Designated State (74) Representative BW GM GH KE LS MW MZ NA SL FISHER CORMACK & BOTHA SD SZ TZ UG ZM ZW (51) International Classification: (54) Title Novel use of antihistamine agents for the preventative or early treatment of inflammatory syndromes, in particular those triggered by togavi ruses (57) Abstract The present invention relates to the use of at least one antihistamine agent for the preparation of a medicament for use in the preventive or early treatment of inflammatory syndromes of viral origin, in particular arthritis of the distal joints, more particularly those triggered by togaviruses. The invention also relates to a combination product of at least one antihistamine agent and of at least one antiserotonin agent for its simultaneous, separate or sequential use in preventive or early therapy for inflammatory syndromes of viral origin, in particular arthritis of the distal joints, more particularly those triggered by togaviruses. (56) Documents Cited : The present invention relates to the use of at least one antihistamine agent for the preparation of a medicament for use in the preventive or early treatment of inflammatory syndromes of viral origin, in particular arthritis of the distal joints, more particularly those triggered by togaviruses. The invention also relates to a combination product of at least one antihistamine agent and of at least one antiserotonin agent for its simultaneous, separate or sequential use in preventive or early therapy for inflammatory syndromes of viral origin, in particular arthritis of the distal joints, more particularly those triggered by togaviruses. Use of at least one H1-antihistamine of phenothiazine type, or an addition salt thereof with a pharmaceutically acceptable acid or base, to prepare a medicinal product intended for the preventive or early treatment of viral arthritis, in particular arthritis of the distal joints. Use according to claim 1, characterized in that the viral arthritis is triggered by an alphavirus, in particular the Chikungunya virus, Ross River virus or Barmah Forest virus. Use according to either of claims 1 and 2, characterized in that said phenothiazine H1-antihistamine also contains an antiserotonin component. Use according to any of claims 1 to 3, characterized in that said H1-antihistamine of phenothiazine type is chosen from among alimemazine, aminopromazine, chlorpromazine, cyamemazine, isopromethazine, levopromazine, mequitazine, pipotiazine, promethazine, thioridazine and thiazinamium methylsulfate. Use according to any of claims 1 to 4, characterized in that said medicinal product is in the form of a tablet whose dose of H1-antihistamine of phenothiazine type ranges from 0.5 mg to 200 mg. Use according to claim 5, characterized in that the H1-antihistamine of phenothiazine type is mequitazine. Use according to any of claims 1 to 4, characterized in that said medicinal product is in the form of a syrup whose concentration of H1-antihistamine of phenothiazine type lies between 0.01 and 1 weight-volume percentage. Use according to claim 7, characterized in that the H1-antihistamine of phenothiazine is mequitazine. Combination product of at least one phenothiazine H1-antihistamine and at least one antiserotonin agent for its simultaneous, separate or time-release use as preventive or early therapy for viral arthritis, in particular arthritis of the distal joints. Product according to claim 9, characterized in that the viral arthritis is triggered by an alphavirus, in particular the Chikungunya virus, Ross River virus or Barmah Forest virus. Product according to either of claims 9 and 10, characterized in that the H1-antihistamine of phenothiazine is chosen from among alimemazine, aminopromazine, chlorpromazine, cyamemazine, isopromethazine, levopromazine, mequitazine, pipotiazine, promethazine, thioridazine and thiazinamium methylsulfate. Product according to any of claims 9 to 11, characterized in that the antiserotonin agent is chosen from among amixetrine, bencyclane, chlorphenoxamine, chlorprothixene, dimetotiazine, fenpentadiol, medifoxamine, methdilazine, perizacin, oxaflumazine, risperidon, ritanserin, seroquel, olanzapin, mesulergin, mianserin, ritanserin, granisetron, dihydroergotamine, dolasetron, ondensetron, ergotamine, flopropione, ketanserin, methylergometrin, methysergide, naftidrofuryl, tolazolin and tropisetron.